Jonah Feldman

Data from a phase 2 trial of atezolizumab with or without radiotherapy showed some antitumor activity in advanced squamous cell carcinoma of the penis, despite failing to meet the primary end point of progression-free survival.

Although sintilimab improved overall response rates and maintained a tolerable safety profile for patients with metastatic or recurrent pancreatic adenocarcinoma, it did not improve overall or progression-free survival.

Acalabrutinib produced positive quality-adjusted survival benefits over other treatment options for patients with relapsed/refractory chronic lymphocytic leukemia.

Standard of care treatment was superior to the combination of ibrutinib plus venetoclax in terms of decreasing minimal residual disease for previously untreated patients with chronic lymphocytic leukemia.

Premenopausal women with hormone receptor-positive, HER2-negative breast cancer saw a survival benefit when treated with adjuvant chemotherapy.